Dr. John Burnett Erskine, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 31 Hall Dr, Amherst, MA 01002 Phone: 413-256-8561 Fax: 413-256-4421 |
News Archive
The New York Times reports that safety rules for biotechnology workers sometimes expose them to dangerous pathogens. "Whether handling deadly pathogens for biowarfare research, harnessing viruses to do humankind's bidding or genetically transforming cells to give them powers not found in nature, the estimated 232,000 employees in the nation's most sophisticated biotechnology labs work amid imponderable hazards. And some critics say the modern biolab often has fewer federal safety regulations than a typical blue-collar factory."
As Congress considers legislation to reform prescription drug pricing, a new analysis conducted by the West Health Policy Center and released by its Council for Informed Drug Spending Analysis (CIDSA) estimates that the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) could result in hundreds of billions of dollars in lower commercial health insurance costs by 2030.
A three-year follow-up study has shown that an alternate treatment for obstructed arteries in the leg may be warranted. The results are from a clinical trial comparing primary nitinol stent implantation with balloon angioplasty. This examination of the study provides a long-term assessment of the two procedures, which is favorable for the primary stent.
In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.
› Verified 2 days ago